Primary Application of Radiofrequency Ablation after Locally Progression of EGFR-TKIs in Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2016.12.09
- VernacularTitle:射频消融在EGFR-TKIs治疗非小细胞肺癌后局部进展的初步临床应用
- Author:
LIU BAODONG
1
;
LI YUANBO
;
HU MU
;
LIU LEI
;
QIAN KUN
;
WANG RUOTIAN
Author Information
1. 首都医科大学宣武医院胸外科
- Keywords:
Epidermal growth factor receptor tyrosine kinase inhibitors;
Lung neoplasms;
Locally progression;
Ra-diofrequency ablation
- From:
Chinese Journal of Lung Cancer
2016;19(12):859-863
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Epidermal growth factor receptor tyrosine kinase in hibitors (EGFR-TKIs) is one of the foundamental treatment for non-small cell lung cancer (NSCLC) with EGFR mutation, however some patients might develop locally progression in primary site. The aim of this study is to assess the clinical application of radi of requency ablation atfer locally progression of NSCLC while receving EGFR-TKIs.Methods Twenty-eight eligible NSCLC patients were enrolled. Effcacy and Safety data of radiofrequency ablation followed by EGFR-TKIs or chemotherapy were collected.Results None of patients had died during peri-operation period. hTe average follow-up time was 17.25 months. Locally progression rate was 10.7% (3/28), and locally progression time was 16.6 months. hTe average progression-free survival was (24.55±5.36) (95%CI:14.04-35.05), and the average overall survival was (25.57±5.45)(95%CI:14.88-36.27). Patients were divided into EGFR-TKIs group and chemotherapy group atfer radi of requency ablation. The average progression-free survival of the two groups were (27.82±7.58)(95%CI:12.97-42.68) and (17.88±3.76)(95%CI:10.52-25.25)(P>0.05) respectively. hTe average OS (overall survival) was (29.42±7.68)(95%CI:14.36-44.48) and (18.44±3.87)(95% CI:14.89-36.27)(P>0.05) in two groups. Conclusion Radi of requency ablation combined with EGFR-TKIs or chemotherapy could prolong progression-free survival and overall survival of EGFR mutant NSCLC patients who had developed locally progression in primary site during EGFR-TKIs treatment.
